ArticleCytoJournal2026
Development and validation of a multiparameter prognostic model for extranodal natural killer/T-cell lymphoma: Integration of clinical, pathological, and molecular biomarkers.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The objectives of the study are to develop and validate a novel prognostic model for extranodal natural killer/T-cell lymphoma (ENKTCL) by integrating clinical and pathological parameters. Material and Methods: We retrospectively analyzed 106 patients with ENKTCL (2008-2020) from the Department of Pathology of Yantai Yuhuangding Hospital and the Affiliated Hospital of Nantong University, constructing the novel international prognostic index (NIPI) model through multivariable Cox regression of immunohistochemistry (IHC) markers (age, MTP53, Ki-67, lactate dehydrogenase, hemoglobin, platelet-tolymphocyte ratio) and quantitative dot blot (QDB) tumor microenvironment features. Results: The model demonstrated significant risk stratification ( Conclusion: NIPI provides improved risk stratification for ENKTCL, and QDB-based analysis offers enhanced precision in individualized therapy. This model addresses the unmet needs for ENKTCL prognostication and warrants further multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.